A Phase 1 Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 17 May 2019
Price : $35 *
At a glance
- Drugs Olaparib (Primary) ; Bevacizumab; Cisplatin; Paclitaxel; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 15 May 2019 Planned End Date changed from 1 Apr 2019 to 1 Apr 2020.
- 15 May 2019 Planned primary completion date changed from 1 Apr 2019 to 1 Apr 2020.
- 01 May 2018 Planned End Date changed from 1 Apr 2018 to 1 Apr 2019.